학술논문

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Document Type
article
Source
Frontiers in Oncology, Vol 13 (2024)
Subject
renal cell carcinoma
lenvatinib
pembrolizumab
sunitinib
bone metastases
liver metastases
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2234-943X